Consumer group sues over Nexium ads

Share this article:
A consumer group has filed a lawsuit against AstraZeneca in California, claiming marketing of AZ's Nexium is deceptive. The suit, filed in California Superior Court in Los Angeles, alleges that AstraZeneca used misleading information to convince consumers Nexium was a significantly better drug than Prilosec in an effort to redirect loyalty. "AstraZeneca knew that with the expiration of their Prilosec patent, [it] would lose market share and profits. We intend to show that they initiated a plan to deceive consumers and recoup those lost revenues," said Steve Berman, lead attorney for the plaintiffs. "This suit is a response to their deception and is a message to AstraZeneca and all pharmaceutical companies that they will be accountable to consumers for
their actions."
AstraZeneca refutes the allegations stating that the data backs up claims made in the consumer ads.
"There is a clear difference with Nexium – better acid control and better healing," said Michele Meeker, an AstraZeneca spokeswoman. "The data we have supports that."
The Nexium consumer campaign was created by New York-based Saatchi & Saatchi, a unit of Publicis. A Publicis spokeswoman had no comment regarding the lawsuit.
The suit was filed by the Prescription Access Litigation Project (PAL), comprised of
American Federation of Labor – Congress of Industrial Organizations (AFL-CIO) the Congress of California Seniors, and the California Alliance for Retired Americans.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...